Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: Randomised trial

Lancet

Volumn 363, Issue 9404, 2004, Pages 192-196

  Van Koningsveld, R ^a   Schmitz, P I M ^a   Van Der Meche F G A ^a   Visser, L H ^a,b   Meulstee, J ^a,c   Van Doorn, P A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CPRLab   (Netherlands)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PLACEBO;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY WEIGHT; CEREBROVASCULAR ACCIDENT; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GASTROINTESTINAL HEMORRHAGE; GLUCOSE BLOOD LEVEL; GUILLAIN BARRE SYNDROME; HEART ARREST; HEART FAILURE; HUMAN; HYPERTENSION; HYPOVOLEMIC SHOCK; LUNG INSUFFICIENCY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE WEAKNESS; PARESIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCORING SYSTEM; SEPSIS; SIDE EFFECT; STANDARDIZATION; URINARY TRACT INFECTION; WALKING;

EID: 1642452717     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)15324-X     Document Type: Article

References (27)

1. Rees J.H., Thompson R.D., Smeeton N.C., Hughes RAC. Epidemiological study of Guillain-Barré syndrome in south east England. J Neurol Neurosurg Psychiatry. 64:1998;74-77.
2. van Koningsveld R., Van Doorn P.A., Schmitz P.I.M., Ang C.W., van der Meché FGA. Mild forms of Guillain-Barré syndrome in an epidemiologic survey the Netherlands. Neurology. 54:2000;620-625.
3. Merkies I.S., Schmitz P.I., Samijn J.P., van der Meché F.G., van Doorn P.A. Fatigue in immune-mediated polyneuropathies. Neurology. 53:1999;1648-1654.
4. de Jager A.E.J., Minderhoud J.M. Residual signs in severe Guillain-Barré syndrome: analysis of 57 patients. J Neurol Sci. 104:1991;151-156.
5. Fletcher D.D., Lawn N.D., Wolter T.D., Wijdicks E.F. Long-term outcome in patients with Guillain-Barré syndrome requiring mechanical ventilation. Neurology. 54:2000;2311-2315.
6. Hughes R.A., Newsom-Davis J.M., Perkin G.D., Pierce J.M. Controlled trial of prednisolone in acute polyneuropathy. Lancet. 2:1978;750-753.
7. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet. 341:1993;586-590.
8. Hughes RAC, van der Meché FGA. Corticosteroids for Guillain-Barré syndrome (Cochrane Review). In: The Cochrane Library, issue 3. Oxford: Update Software, 2003.
9. Plasmapheresis and acute Guillain-Barré syndrome. Neurology. 35:1985;1096-1104.
10. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol. 22:1987;753-761.
11. van der Meché FGA, Schmitz PIM, Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326: 1123-1129.
12. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet. 349:1997;225-230.
13. Hahn A.F. Guillain-Barré syndrome. Lancet. 352:1998;635-641.
14. Hughes RA, Raphael JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome (Cochrane Review). In: The Cochrane Library, issue 3. Oxford: Update Software, 2003.
15. Hadden R.D.M., Karch H., Hartung H.P., et al. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology. 56:2001;758-765.
16. Ropper A.H., Wijdicks E.F.M., Truax B.T. Guillain-Barré syndrome. 1991;FA Davis Company, Philadelphia.
17. Dyck P.J., O'Brien P.C., Oviatt K.F., et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol. 11:1982;136-141.
18. Hughes R., Bensa S., Willison H., et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 50:2001;195-201.
19. Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. Ann Neurol. 35:1994;749-752.
20. Asbury A.K., Cornblath D.R. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol. 27:(suppl):1990;S21-S24.
21. McKhann G.M., Griffin J.W., Cornblath D.R., Mellits E.D., Fisher R.S., Quaskey S.A. Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol. 23:1988;347-353.
22. Aids to the investigation of the peripheral nervous system. 1976;HMSO, London.
23. Visser L.H., van der Meché F.G.A., Meulstee J., et al. Cytomegalovirus infections and the Guillain-Barré syndrome, the clinical, electrophysiological and prognostic features. Neurology. 47:1996;668-673.
24. Geller N.L., Pocock S. Interim analysis in randomised clinical trials: ramifications and guidelines for practitioners. Biometrics. 43:1987;213-223.
25. Kazatchkine M.D., Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 345:2001;747-755.
26. Berciano J., Figols J., García A., et al. Fulminant Guillain-Barré syndrome with universal inexcitability of peripheral nerves: a clinicopathological study. Muscle Nerve. 20:1997;846-857.
27. Berciano J. Rational therapy of Guillain-Barré syndrome. Lancet. 351:1998;754-755.